HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Two HDAC inhibitors (HDACi), vorinostat® and romidepsin® (FK228) have achieved good clinical efficacy in CTCL with objective responses of 25–30%, leading to the FDA approval of both drugs for the treatment of CTCL in 2006 and 2009, respectively [29].